Biotechs
Multiple +ive patterns1 trend retest
2 trend-based fibo. bounce zone
3 possible three bottoms (Super Pattern)
tkai long risk/reward 1.64Tkai massive upside potential. In other words, buy between .99 and current price 1.06 and aim to get out in the 1.2's. Current price is the high point of first wave up (the XA)..price descended appropriately (1--> .618) for support, and moved higher between the 1.21 and 1.41 exetension of XA. The following downtrend in price should suggest a move upwards to at LEAST 1.2s.
Threshold PharmcaceuticalsTHLD triggered my first level 1.29$ above the pennie mode. Main reason for it might be the release of phase III data from its clinical stage studies of Tarloxotinib. The data will be released somewhere in September. My next levels are 2.15$ and 2.75$.
What to do with Novavax nowElliot wave suggests downward momentum for the past two years, and yesterday NVAX investors got their hearts crushed. Where can it go from here? Based on yesterdays market activity, I see it headed towards the 1.618 retracement regardless of upward or doward movement. so, if it heads further south we could see high 80s but under a dollar, and if demand increases it would head towards about 2.08. So in other words, it could lose about, say 30-40 more cents but has the potential to rise close to double that at 2.08. In fact, I'd say it's likely to rise to about 2 to stay within LT S/R/. Let me know your thoughts!
DiaMedica next targets 0.378, 0.591, 0.763$Did you ever heard about kidney and heart insufficiencies to be the most accompanying disease? I don't refer on diabetes type 2 but the real first sign an human organism is suffering from serious weakness. Here is DiaMedica with KLK1 and DM199 to reconstruct bradykinin preventing reduced blood flow after strokes or chronical diseases which narrow blood vessel.
Technically I think we could pass 0.320$ (=2009er low) as buytigger and proceed to 0.591, 0.934$. I am not prohpetic so I avoid shouting out levels out of the penny range.
Sernova$SVA made a good perfo in 2015 and for me this is a buy. Next target is 0.319 again and 215 high 0.4$. My extensions are on 0.54 and 0.635$.
Eyes on $BLUBellus Health got a massive gap which droves the the company back into the penniestock level May this year. Still no buyers interests appear for KIACTA™. But as we saw yesterday on Navidea prices there're more examples on the market which show Investors the opposite hidden interests in good studies to buy for producing.
Microbix on watchlistMicrobix is near on it's alltime lows, the website is offline but last news I found was a growth net income per share $0.001 in Q3. Worth watching it
Navidea, just wow!just wow, to be hinest the perfo of this yesterday I didn' expect ! I launched this stock long time ago and it happened absolutely nothing. As always you can't expect a pennie breakes out at least or would be overtaken and supplies a rally like this....
So here I would be careful even if the move was driven by fundamental sale of Lymphoseek to Cardinal Health it just pimped capacity of Navideas pipeline with fresh money. I won't belittle the move at all and I'm happy that there will be another step against head cancer as well as Peregrine does. Since I didn't Publish this idea I would reccomand buy limits to put between 0.64-0.55$ even if there will be no entry triggered.
Stemcells Inc. is no Pennystock anymoreStemcells Inc. has beaten all my expectations. Since merging with Microbot there is a lot of cashflow running in. Investors of Microbot hold up to 75% in longer perspective so this picking still slides hihgly potential to be the next Gilead. Next target would proceed the incompleted gap close from May while it rumoured the company puts all operations. This shows the thin line between dropping to zero and big surprises in picking pennies. :))))))))))))))))))))))
:) PFIZER TOPPED OUT :0GO HSORT GUYS WITH LEAP OPTIONS OF NEEDED.
PFIZER TOPPED OUT.
buy the rumor sell the news " Pfizer to Buy Medivation for $14 Billion" The bigger the buy the greater the fall.
www.wsj.com
PFIZER is trying her last bet to survive but eventually will fall. wish Pfizer CEO and all the board directors can see it for them to look for new job or polish up resume or start networking before it gets worse.
From 199 high the RED line is touching to new high. As soon as it breaks the light solid (not the dotted one) Green line it will fll pretty hard even though there will be a short term bounce from belwo solid green line but eventually if you hold you short from now on you will be a gainer for coming years. But question is do you have the patience or the risk appetite. Enjoy your lunch guys.
HIGH TIME TO BUY RENEWABLE OPERATION COMPANIESLooking for places to invest your money in light of cheap oil prises? Probably it is a high time the other way around. Companies (such as Aemetis) involved in biochemistry and renewable operations are picking up steam to replace often overpriced oil giants.
Technical analysis implies the same thing as Aemetis, Inc. touched it 2009 low and ready to jump up any time soon. Considering this configuration we enter the market today (09.08.2016) and expect a move to 12$.
For more ideas visit: mercuriusam.wordpress.com
IBB BIOTECHRECENTLY most of the biotech companies are doing bad but somehow this ETF is going up. I saw weakness in technical analysis of monthly charts but weekly and daily needs to go down before shorting. Think this IBB bull will be ashort lived and once broken it will be a free fall zone. Leap options for short side will be a good bet. Don't go short yet but a good candidate for follow up.
BIOTECH sector on situation!Either going to bounve, or brake nasty... I think it's going to bounce and then die. Look for neg divergences to short later...
Short biotechnology again near trend line resistance Biotech bubble has burst.
Every rallies are to be sold, and despite the euphoria/new highs in S&P and Nasdaq have barely registered a decent retracement in the biotech sector..
Here's a larger picture of how far biotechs have went since 2008:
The uptrend in S&P is limited, and it will only be a matter of time before it collapses off this rising wedge. However it is also risky to go against Janet Yellen (FED) with unlimited cash in its balance sheet. A short on a specific sector would be a much safer bet.
-------------------
I'm long on ZBIO (3x short biotech ETF) at 22.51, with a target around $30~40.
ARNA - Ascending Wedge breakSeems like a nice short here with SL above daily high:
- Ascending Wedge break + pullback
- Divergence on the Sto
- On higher timeframes it is bearish
